Addex Spin-out Neurosterix Completes Phase 1 Schizophrenia Drug Trial

Key Facts

1Addex Therapeutics announced that its spin-out company Neurosterix successfully completed Phase 1 studies for the drug NTX-253.

2Neurosterix plans to move the drug, a muscarinic M4 receptor positive allosteric modulator, into Phase 2 trials for schizophrenia.

Addex Therapeutics announced that its spin-out company Neurosterix successfully completed Phase 1 studies for the drug NTX-253. Reuters reported that the drug, a muscarinic M4 receptor positive allosteric modulator, met its Phase 1 objectives, allowing the program to advance.

Neurosterix now plans to move the candidate into Phase 2 trials specifically targeting schizophrenia and other psychiatric disorders. In equity markets, ADXN closed at $3.2186 on October 9, 2026, having traded between a session high of $3.249 and a low of $2.97.